[Treatment of pulmonary hypertension in COPD: is there hope for the better?].
The aim of this study is to prove for a well tolerated medication (clinical and financial) a supplementary effect in improvement prognosis of patients with pulmonary hypertension secondary to COPD, already treated with classical pneumology drugs. Three pts. groups were selected: the first received only classical pneumology treatment, the second with supplementary therapy by IECA and Ca-blockers, the third with supplementary therapy with IECA and nebivolol; the follow-up protocol included clinical and paraclinical status (blood gases, spirometry, ECG, echocardiography, 6 minute walk test) over 3 months. Clinical and paraclinical evolution of the pts. in group 2 and group 3 was significantly better that in pts from group 1. We conclude that addition of IECA + Ca-blocker/IECA + nebivolol therapy at classical pneumology therapy result in a better evolution in pts. with pulmonary hypertension secondary to COPD.